Treatment for rheumatoid arthritis
Anti-GM-CSF antibodies like MOR103, administered at effective doses and frequencies, provide a novel treatment for rheumatoid arthritis, effectively reducing disease activity and joint damage, addressing the limitations of existing therapies.
Patent Information
- Application Number
- JP2024135431
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2012-09-21
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for rheumatoid arthritis, including biological compounds targeting TNFα, B cells, or T cells, fail to effectively benefit many patients, and there is a need for alternative therapeutic interventions targeting granulocyte-macrophage colony-stimulating factor (GM-CSF) to manage inflammation and joint damage.
Development of a clinically effective treatment regimen using anti-GM-CSF antibodies, such as MOR103, administered at specific doses and frequencies to achieve therapeutically effective blood concentrations, either intravenously or subcutaneously, potentially combined with DMARDs like methotrexate.
The anti-GM-CSF antibodies demonstrate significant clinical efficacy in reducing disease activity and inhibiting structural joint damage in rheumatoid arthritis patients, as measured by DAS28 and ACR20 scores, with a safety profile comparable to intravenous administration.
Smart Images

Figure 2024156992000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis, and methods for the treatment of rheumatoid arthritis using such antibodies. Anti-GM-CSF antibodies, particularly MOR103, are administered to patients suffering from rheumatoid arthritis in doses that are effective in a clinical setting. [Background technology]
[0002] Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects 0.5%-1% of the adult population worldwide. RA primarily affects the joints and is characterized by chronic inflammation of synovial tissues, which can eventually cause destruction of cartilage, bone and ligaments, resulting in joint deformity. RA has a peak incidence between 40 and 60 years of age and affects mainly women. The cause of RA is unknown, but certain histocompatibility antigens are associated with worse outcomes. Nonsteroidal anti-inflammatory drugs (NSAIDs) only provide symptomatic relief. Disease-modifying antirheumatic drugs (DMARDs), the cornerstone of RA treatment throughout all stages of the disease, maintain or improve physical function and slow radiographic joint damage. Proinflammatory cytokines, such as tumor necrosis factor-alpha (TNFα), interleukin-1, interleukin-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which cause immune cell activation and proliferation, have been found to be increased in inflamed joints.
[0003] More recently, biological compounds targeting tumor necrosis factor alpha (TNFα), B cells, or T cells, such as antibodies, have been used to treat RA, but many patients still do not respond to these treatments. Colony-stimulating factors (CSFs) have been proposed as a potential therapeutic intervention point for inflammatory diseases such as RA (reviewed, for example, in Nat Rev Immunol (2008) 8, 533-44 or Nat Rev Rheumatol (2009) 5, 554-9). One such CSF is granulocyte-macrophage colony-stimulating factor (GM-CSF).
[0004] MOR103 is a fully human anti-GM-CSF antibody (Mol Immunol (2008) 46, 135-44; WO 2006 / 122797). MOR 103 is also in Phase Ib clinical trials for multiple sclerosis. The present invention describes the development of a clinically effective treatment regimen involving MOR103 for RA. Summary of the Invention
[0005] In one aspect, the invention provides an anti-GM-CSF antibody for use in treating a patient suffering from rheumatoid arthritis, wherein the antibody is administered to the patient in a manner that achieves a therapeutically effective concentration of the antibody in the patient's blood that is equal to or greater than when the antibody is administered intravenously every week for at least 4 weeks at a dose of at least 1.0 mg / kg.
[0006] In another aspect, the present invention also provides a method of treating a patient suffering from rheumatoid arthritis, the method comprising administering an anti-GM-CSF antibody to the patient in a manner that achieves a therapeutically effective concentration of the antibody in the patient's blood that is equal to or greater than when the antibody is administered intravenously weekly for at least 4 weeks at a dose of at least 1.0 mg / kg.
[0007] In one embodiment, the anti-GM-CSF antibody is administered intravenously, optionally at a dose of at least 1.0 mg / kg, or at a dose of about 1.0 mg / kg or about 1.5 mg / kg, hi one embodiment, the anti-GM-CSF antibody is administered weekly for at least four weeks.
[0008] In certain embodiments, the anti-GM-CSF antibody is administered subcutaneously, optionally at a dose of at least 2.0 mg / kg, or at a dose of about 2.0 mg / kg, about 3.0 mg / kg, or about 4.0 mg / kg. In certain embodiments, the anti-GM-CSF antibody is administered every other week, every month, or every other month. In other embodiments, the antibody is administered at a fixed dose of about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 300 mg, or about 400 mg. The administration of the fixed dose can be weekly, every two weeks, every three weeks, every four weeks, or every six weeks.
[0009] In one embodiment, the dose of anti-GM-CSF antibody administered to the patient, and the frequency of said administration, is sufficient to result in and maintain a serum concentration of said antibody of at least 2 μg / ml in said patient for the duration of said treatment.
[0010] In another aspect, the invention provides an anti-GM-CSF antibody comprising an HCDR1 region of the sequence GFTFSSYWMN (SEQ ID NO:2), an HCDR2 region of the sequence GIENKYAGGATYYAASVKG (SEQ ID NO:3), an HCDR3 region of the sequence GFGTDF (SEQ ID NO:4), an LCDR1 region of the sequence SGDSIGKKYAY (SEQ ID NO:5), an LCDR2 region of the sequence KKRPS (SEQ ID NO:6) and an LCDR3 region of the sequence SAWGDKGM (SEQ ID NO:7) for use in treating a patient suffering from rheumatoid arthritis, wherein the antibody is administered to the patient in a manner that achieves a therapeutically effective antibody concentration in the patient's blood that is equivalent or higher compared to intravenous administration of the antibody when administered weekly for at least 4 weeks at a dose of at least 1.0 mg / kg.
[0011] In another aspect, the invention provides an anti-GM-CSF antibody, the antibody comprising an HCDR1 region of the sequence GFTFSSYWMN (SEQ ID NO:2), an HCDR2 region of the sequence GIENKYAGGATYYAASVKG (SEQ ID NO:3), an HCDR3 region of the sequence GFGTDF (SEQ ID NO:4), an LCDR1 region of the sequence SGDSIGKKYAY (SEQ ID NO:5), an LCDR2 region of the sequence KKRPS (SEQ ID NO:6) and an LCDR3 region of the sequence SAWGDKGM (SEQ ID NO:7) for use in treating a patient suffering from rheumatoid arthritis, the antibody being administered intravenously at a dose of about 1.0 mg / kg, or at a dose of about 1.5 mg / kg, administered weekly for at least 4 weeks.
[0012] In another aspect, the invention provides an anti-GM-CSF antibody for use in treating a patient suffering from rheumatoid arthritis, wherein the antibody is administered to the patient in a manner that achieves a therapeutically effective concentration of the antibody in the patient's blood that is equal to or greater than when the antibody is administered intravenously weekly for at least 4 weeks at a dose of at least 1.0 mg / kg or at least 1.5 mg / kg, and wherein the anti-GM-CSF antibody is administered in combination with a DMARD such as methotrexate.
[0013] In certain embodiments, administering the antibody to achieve such a therapeutically effective amount comprises intravenously administering the antibody at a dose of at least 0.6, at least 0.7, at least 0.8, at least 0.9, or at least 1.0 mg / kg. In other embodiments, the antibody of the invention is administered intravenously at a dose of about 1.0 mg / kg or at a dose of about 1.5 mg / kg. Administration can be monthly, biweekly (every two weeks), or weekly.
[0014] In another aspect, the invention provides an anti-GM-CSF antibody for use in treating a patient suffering from rheumatoid arthritis, wherein the antibody is administered subcutaneously to the patient in a manner that achieves a therapeutically effective blood concentration of the antibody in the patient that is equal to or greater than when the antibody is administered intravenously weekly for at least four weeks at a dose of at least 1.0 mg / kg or at least 1.5 mg / kg, and wherein the anti-GM-CSF antibody is administered in combination with a DMARD such as methotrexate.
[0015] In certain embodiments, administration of the antibody to achieve such a therapeutically effective amount comprises subcutaneous administration of the antibody at a dose of at least 1.0, at least 1.5, at least 2.0, at least 2.5, at least 3.0, at least 3.5 or at least 4.0 mg / kg. In other embodiments, the antibody of the invention is administered subcutaneously at a dose of about 2.0 mg / kg, at a dose of about 3.0 mg / kg or at a dose of about 4.0 mg / kg. Administration can be monthly, biweekly (every two weeks) or weekly.
[0016] In certain embodiments, administration of the antibody to achieve such a therapeutically effective amount comprises subcutaneous administration of the antibody at a fixed dose of about 40 mg, about 75 mg, about 100 mg, about 140 mg, about 150 mg, about 180 mg, about 200 mg, about 280 mg, about 300 mg, or about 400 mg. Fixed dose administration can be weekly, every 2 weeks, every 3 weeks, every 4 weeks, or every 6 weeks.
[0017] In another aspect, the present invention provides a method of treating a patient suffering from rheumatoid arthritis, the method comprising: (i) a dose of at least 1.0 mg / kg; or (ii) at a fixed dose of 40 mg to 400 mg administering an anti-GM-CSF antibody subcutaneously to the patient. The anti-GM-CSF antibody may be administered to the patient in a manner that achieves a serum concentration of the antibody of at least 2 μg / ml in the patient during the course of the treatment. The antibody may be administered to the patient in a manner that achieves a therapeutically effective concentration of the antibody in the patient's blood that is equal to or greater than when the antibody is administered intravenously weekly for at least four weeks at a dose of at least 1.0 mg / kg.
[0018] In another aspect, the invention provides an anti-GM-CSF antibody for inhibiting the progression of structural joint damage in a patient with rheumatoid arthritis comprising administering the antibody to the patient in a manner that achieves a therapeutically effective concentration of the antibody in the patient's blood that is equivalent to or greater than intravenous administration of the antibody when administered weekly for at least four weeks at a dose of at least 1.0 mg / kg. [Brief description of the drawings]
[0019] [Figure 1] FIG. 1 shows the amino acid and DNA sequences of MOR04357. [Diagram 2] Figure 2 shows a comparison of the mean change in DAS28 score after 4 weeks (left panel) and 8 weeks (right panel) of treatment. The change in DAS28 score is compared to the baseline value, i.e., the disease state before treatment. [Diagram 3] Figure 3 shows the mean ACR20 scores for all treatment groups after 4 weeks. An increase in ACR20 score corresponds to an improvement in disease severity. [Figure 4] Figure 4 shows the mean ACR20 scores for all treatment groups after 8 weeks. An increase in ACR20 score corresponds to an improvement in disease severity. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] explanation The terms "GM-CSF" and "GMCSF" refer to the protein known as GM-CSF or Granulocyte Macrophage Colony Stimulating Factor, which has the following synonyms: Colony Stimulating Factor 2, CSF2, GMCSF, GM-CSF, Granulocyte Macrophage Colony Stimulating Factor, MGC131935, MGC138897, Molgramostin, Sargramostim. Human GM-CSF has the following amino acid sequence (UniProt P04141): MWLQSLLLLGTVACSISAPARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNET VEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETS CATQIITFESFKENLKDFLLVIPFDCWEPVQE (sequence number 1).
[0021] "MOR103" is an anti-GM-CSF antibody whose amino acid and DNA sequences are shown in Figure 1. "MOR103" and "MOR04357" and "MOR4357" are used synonymously to refer to the antibody shown in Figure 1. MOR04357 contains an HCDR1 region of the sequence GFTFSSYWMN (SEQ ID NO:2), an HCDR2 region of the sequence GIENKYAGGATYYAASVKG (SEQ ID NO:3), an HCDR3 region of the sequence GFGTDF (SEQ ID NO:4), an LCDR1 region of the sequence SGDSIGKKYAY (SEQ ID NO:5), an LCDR2 region of the sequence KKRPS (SEQ ID NO:6), and an LCDR3 region of the sequence SAWGDKGM (SEQ ID NO:7). ... The variable heavy chain and sequence of QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGA TYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS (SEQ ID NO: 8) The variable light chain is: DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGS NSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQ (SEQ ID NO: 9).
[0022] In one embodiment, the antibody used in the present invention is an antibody specific for GM-CSF. In another embodiment, the antibody used in the present invention is an antibody specific for a polypeptide encoding an amino acid sequence comprising SEQ ID NO:1.
[0023] As used herein, "specifically for" or "specifically binds to" refers to an antibody that selectively or preferentially binds to GM-CSF. Preferably, the binding affinity for the antigen is greater than or equal to 10 -9 mol / l or less (e.g. 10 -10 mol / l), preferably 10 -10 mol / l or less (e.g. 10 -12 The binding affinity is measured by standard binding assays such as surface plasmon resonance (BIACORE®).
[0024] In one embodiment, the antibody used in the present invention is MOR103. In another embodiment, the antibody used in the present invention is an antibody comprising an HCDR1 region of the sequence GFTFSSYWMN (SEQ ID NO:2), an HCDR2 region of the sequence GIENKYAGGATYYAASVKG (SEQ ID NO:3), an HCDR3 region of the sequence GFGTDF (SEQ ID NO:4), an LCDR1 region of the sequence SGDSIGKKYAY (SEQ ID NO:5), an LCDR2 region of the sequence KKRPS (SEQ ID NO:6), and an LCDR3 region of the sequence SAWGDKGM (SEQ ID NO:7). ... The variable heavy chain and sequence of QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGA TYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS (SEQ ID NO: 8) The antibody comprises a variable light chain of the following sequence: DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQ (SEQ ID NO: 9). In another embodiment, the antibody used in the present invention is an antibody that cross-competes with an antibody comprising an HCDR1 region of the sequence GFTFSSYWMN (SEQ ID NO: 2), an HCDR2 region of the sequence GIENKYAGGATYYAASVKG (SEQ ID NO: 3), an HCDR3 region of the sequence GFGTDF (SEQ ID NO: 4), an LCDR1 region of the sequence SGDSIGKKYAY (SEQ ID NO: 5), an LCDR2 region of the sequence KKRPS (SEQ ID NO: 6), and an LCDR3 region of the sequence SAWGDKGM (SEQ ID NO: 7). In another embodiment, the antibody used in the present invention is an antibody that binds to the same epitope as an antibody specific for GM-CSF, including an HCDR1 region of the sequence GFTFSSYWMN (sequence number 2), an HCDR2 region of the sequence GIENKYAGGATYYAASVKG (sequence number 3), an HCDR3 region of the sequence GFGTDF (sequence number 4), an LCDR1 region of the sequence SGDSIGKKYAY (sequence number 5), an LCDR2 region of the sequence KKRPS (sequence number 6), and an LCDR3 region of the sequence SAWGDKGM (sequence number 7).
[0025] The term "antibody" is used in the broadest sense and specifically includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) composed of at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.
[0026] As used herein, the term "antibody fragment" includes a portion of an intact antibody that retains the ability to bind to an antigen. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
[0027] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical and / or bind to the same epitope, except for possible mutations that may occur during the production of the monoclonal antibody, although such mutations are usually present in minor amounts. In contrast to polyclonal antibody preparations, which usually contain different antibodies against different determinants (epitopes), each monoclonal antibody targets a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they are uncontaminated by other immunoglobulins.
[0028] Monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chains are identical to or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chains are identical to or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
[0029] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In most cases, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and capacity. In some cases, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may contain residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. Usually, humanized antibodies comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin, and all or substantially all of the FRs are those of human immunoglobulin sequences, except for FR substitutions as noted above. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region, typically that of a human immunoglobulin.
[0030] A "human antibody" as used herein includes an amino acid sequence structure that corresponds to that of an antibody obtained from a human B cell, including antigen-binding fragments of a human antibody. Such antibodies can be identified or produced by a variety of techniques, including, but not limited to, production by transgenic animals (e.g., mice) that are capable of producing human antibodies in the absence of endogenous immunoglobulins upon immunization; selection from phage display libraries expressing human antibodies; production by in vitro activated B cells; and isolation from human antibody-producing hybridomas.
[0031] In certain embodiments, the antibodies used in the present invention are monoclonal antibodies.
[0032] In other embodiments, the antibodies used in the present invention are chimeric, humanized, or human antibodies. In a preferred embodiment, the antibodies used in the present invention are human antibodies.
[0033] In one embodiment, the antibody used in the invention is administered in combination with an additional drug to treat RA.
[0034] The additional agent may be one or more agents, including, for example, an immunosuppressant, a nonsteroidal anti-inflammatory drug (NSAID), a disease-modifying antirheumatic drug (DMARD) such as methotrexate (MTX), an anti-B cell surface marker antibody such as an anti-CD20 antibody (e.g., rituximab), a TNF-α inhibitor, a corticosteroid, and a co-stimulatory modifier, or any combination thereof. Optionally, the second or additional drug is selected from the group consisting of a non-biologic DMARD, an NSAID, and a corticosteroid.
[0035] These additional drugs are usually used in the same doses and routes of administration as those used above and below. When such additional drugs are used, they are preferably used in smaller amounts than in the absence of the first drug, especially in subsequent administrations past the initial administration with the first drug, to eliminate or reduce side effects caused thereby. Concomitant administration of additional drugs includes co-administration (concurrent administration) using separate formulations or a single pharmaceutical formulation, and sequential administration in any order, preferably with a period when both (or all) active substances (drugs) exert their biological activity simultaneously.
[0036] The term "DMARD" stands for "disease-modifying antirheumatic drugs ( D isease- M odifying A nti- R heumatic DDMARDs are non-biological or classical DMARDs, including, inter alia, hydroxychloroquine, sulfasalazine, methotrexate, leflunomide, azathioprine, D-penicillamine, gold salts (oral), gold salts (intramuscular), minocycline, cyclosporines such as cyclosporine A and topical cyclosporine, and TNF-inhibitors, including their salts, variants, and derivatives. Exemplary DMARDs herein are non-biological or classical DMARDs, such as azathioprine, chloroquine, hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine.
[0037] Methotrexate is a particularly preferred DMARD of the invention. Thus, in one embodiment, the antibody used in the invention is administered in combination with a DMARD. In another embodiment, the antibody used in the invention is administered in combination with methotrexate.
[0038] "TNF-inhibitor" as used herein refers to an agent that inhibits some biological function of TNF-α, usually by binding to TNF-α and / or its receptor and neutralizing its activity. Examples of TNF inhibitors include etanercept (ENBREL®), infliximab (REMICADE®), adalimumab (HUMIRA®), certolizumab pegol (CIMZIA®), and golimumab (SIMPONI®).
[0039] "Treatment" of a patient or subject refers to both therapeutic treatment and prophylactic methods. The term "effective amount" or "therapeutically effective" refers to an amount of antibody that is effective for treating rheumatoid arthritis. Such an effective amount may cause any one or more of a reduction in signs or symptoms of RA (e.g., achieving ACR20), a reduction in disease activity (e.g., disease activity score, DAS20), a slowdown in the progression of structural joint damage, or an improvement in physical function. In one embodiment, such clinical response is comparable to that achieved by intravenously administered anti-GM-CSF antibody.
[0040] The antibodies of the present invention may be administered in various suitable forms. Possible forms of administration include systemic administration (subcutaneous, intravenous, intramuscular), oral administration, inhalation, transdermal administration, local application (such as topical creams or ointments) or other methods known in the art. The dose (mg / kg) defined in the present invention refers to milligrams of antibody per kilogram of patient body weight. In vitro cell-based assays have shown that anti-GM-CSF antibody (MOR103) can inhibit several GM-CSF-mediated responses. The responses evaluated include TF-1 cell proliferation, STAT5 phosphorylation, polymorphonuclear neutrophil (PMN) migration, upregulation of CD11b on PMN, upregulation of MHC II on monocytes, and eosinophil survival. Full inhibitory effects were usually achieved at concentrations of anti-GM-CSF antibody of about 0.2 μg / ml. GM-CSF concentrations of up to 1 ng / ml were applied in such studies. For reference, GM-CSF concentrations in synovial fluid from RA patients have been reported to be <500 pg / ml. It is reasonable to assume that GM-CSF concentrations similar to those used in these in vitro studies are present in affected tissues from RA patients.
[0041] To effectively treat RA, it may be important for anti-GM-CSF antibodies to penetrate the synovium. There is evidence to suggest that monoclonal antibodies can distribute within the synovium when administered subcutaneously or intravenously. Based on a predicted penetration rate of 30%, sustained GM-CSF production, and taking into account patient heterogeneity, a minimal or suboptimal clinically effective concentration in RA patients is predicted to be a serum concentration of approximately 2 μg / ml antibody (thus approximately 10-fold higher than the inhibitory concentration obtained from in vitro studies).
[0042] A specific anti-GM-CSF antibody (MOR103) was administered to patients with active rheumatoid arthritis, who received four weekly intravenous doses of 0.3, 1, and 1.5 mg / kg. The anti-GM-CSF antibody demonstrated significant clinical benefits in DAS28, EULAR, ACR20, ACR50, ACR70, and tender joint counts after weekly dosing at 1 and 1.5 mg / kg compared to placebo.
[0043] In certain embodiments, the antibodies of the invention are administered intravenously, hi other embodiments, the antibodies of the invention are administered subcutaneously.
[0044] It is known from other therapeutic antibodies that the concentration that results in a particular blood antibody level when administered intravenously corresponds to about 50-76% of the blood concentration achieved when the same antibody concentration is administered subcutaneously (Meibohm, B.: Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley-VCH, 2006). For MOR103, this ratio was measured to be 52%. That is, a given concentration administered subcutaneously results in a blood concentration that corresponds to about 52% of the blood concentration when the same given concentration is administered intravenously. Thus, the concentration of the subcutaneous formulation needs to be about twice as high to achieve the same drug blood level compared to the intravenous formulation.
[0045] In certain embodiments, the blood levels to be achieved in a patient are comparable to or higher than the blood concentrations achieved by intravenous administration of an antibody of the invention when administered weekly for at least four weeks at a dose of at least 1.0 mg / kg.
[0046] In another embodiment, the blood level to be achieved is equivalent to or higher than the blood level achieved when the antibody of the invention is administered intravenously at a dose of at least 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9 mg / kg every week for at least 4 weeks. In another embodiment, the blood level to be achieved in a patient is equivalent to or higher than the blood level achieved when the antibody of the invention is administered intravenously at a dose of at least 1.0 mg / kg every week for at least 2 weeks or at least 3 weeks. In another embodiment, the blood level to be achieved in a patient is equivalent to or higher than the blood level achieved when the antibody of the invention is administered intravenously at a dose of at least 1.0 mg / kg every other week for at least 2 weeks or at least 4 weeks.
[0047] In some embodiments, the antibodies of the invention are administered intravenously. In other embodiments, the antibodies of the invention are administered intravenously at a dose of at least 0.6, at least 0.7, at least 0.8, at least 0.9, or at least 1.0 mg / kg. In other embodiments, the antibodies of the invention are administered intravenously at a dose of about 1.0 mg / kg or at a dose of about 1.5 mg / kg.
[0048] In one embodiment, the antibody of the present invention is administered subcutaneously. Various dosing schedules have been simulated using subcutaneous delivery of MOR103 to produce plasma concentrations similar to those obtained after 1 mg / kg IV, a dose that has been effective in RA. The majority of the simulations produce trough concentration values higher than 2 μg / mL, a value believed to be the minimum blood concentration required to produce efficacy for anti-GM-CSF antibodies. These studies show that subcutaneous doses of 1, 2, 3 and 4 mg / kg can produce plasma concentrations similar to 1 mg / kg IV, depending on the frequency of administration.
[0049] In other embodiments, the antibodies of the invention are administered subcutaneously at a dose of at least 1.0, at least 1.5, at least 2.0, at least 2.5, at least 3.0, at least 3.5, or at least 4.0 mg / kg. In other embodiments, the antibodies of the invention are administered subcutaneously at a dose of about 2.0 mg / kg, at a dose of about 3.0 mg / kg, or at a dose of about 4.0 mg / kg. In certain embodiments, the antibodies of the invention are administered subcutaneously every other week, every month, or every other month.
[0050] In other embodiments, the antibody of the invention is administered subcutaneously in a fixed dose. In such "fixed dose" treatment, the antibody is administered at a specific fixed concentration, i.e., without taking into account the patient's weight. In certain embodiments, the antibody of the invention is administered in a fixed dose of 40 mg to 400 mg, optionally in a fixed dose of 75 mg, 100 mg, 140 mg, 150 mg, 180 mg, 200 mg, 280 mg, 300 mg, or 400 mg. The administration of the fixed dose can be weekly, every two weeks, every three weeks, every four weeks, or every six weeks. Usually, the antibody is administered in a fixed dose every week.
[0051] In certain embodiments, the antibody is administered at a fixed subcutaneous dose of 40, 56, 70, 75, 100, 140, 150, 180, 200, 210, or 280 mg weekly.
[0052] In certain embodiments, the antibody is administered at a fixed subcutaneous dose of 70, 75, 100, 140, 150, 180, 200, 210, 280 or 300 mg every two weeks.
[0053] In certain embodiments, the antibody is administered at a fixed subcutaneous dose of 100, 140, 150, 180, 200, 210, 280, 300, 320, 350, 360 or 400 mg per month.
[0054] In certain embodiments, the antibody is administered at a dose sufficient to maintain a trough concentration of the antibody of at least 2 μg / mL. The trough concentration of the antibody may be maintained at 2.0 μg / mL, 2.5 μg / mL, 3.0 μg / mL, 3.5 μg / mL, 4.0 μg / mL, 4.5 μg / mL or 5.0 μg / mL over the course of treatment.
[0055] In another embodiment, the antibody is administered at a fixed subcutaneous dose of 28 or 35 mg weekly.
[0056] In one embodiment, the invention provides an anti-GM-CSF antibody for use in treating a patient suffering from rheumatoid arthritis, wherein the antibody is administered to the patient in a manner that achieves a therapeutically effective concentration of the antibody in the patient's blood that is equal to or greater than when the antibody is administered intravenously every week for at least four weeks at a dose of at least 1.0 mg / kg.
[0057] In one embodiment, the invention provides a method of treating a patient suffering from rheumatoid arthritis, the method comprising administering an anti-GM-CSF antibody to the patient in a manner that achieves a therapeutically effective concentration of the antibody in the patient's blood that is equivalent to or greater than when the antibody is administered intravenously weekly for at least four weeks at a dose of at least 1.0 mg / kg.
[0058] In one embodiment, the invention provides an anti-GM-CSF antibody for inhibiting the progression of structural joint damage in a patient with rheumatoid arthritis, comprising administering the antibody to the patient in a manner that achieves a therapeutically effective concentration of the antibody in the patient's blood that is equal to or greater than when the antibody is administered intravenously every week for at least 4 weeks at a dose of at least 1.0 mg / kg.
[0059] The terms "drug" and "medicament" refer to an active drug for treating joint damage or symptoms or side effects associated with rheumatoid arthritis or RA. The term "pharmaceutical formulation" refers to a preparation of the active ingredient, i.e., the antibody of the invention, in a form such that the biological activity of the antibody is effective and does not contain additional ingredients that have unacceptable toxicity to the subject to whom the formulation will be administered. Such formulations are sterile.
[0060] The antibodies herein are preferably produced recombinantly in a host cell transformed with a nucleic acid sequence encoding the heavy and light chains thereof (e.g., the host cell has been transformed with one or more vectors containing the nucleic acid therein). Preferred host cells are mammalian cells, most preferably PER.C6 cells.
[0061] Therapeutic formulations of the antibodies of the present invention are prepared in the form of lyophilized formulations or aqueous solutions for storage by mixing the antibody having the desired purity with optional pharma- ceutically acceptable carriers, excipients, or stabilizers. Acceptable carriers, excipients, or stabilizers are those that are not toxic to recipients at the doses and concentrations used, and include buffers such as phosphate, citrate, histidine, and other organic acids; antioxidants such as ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; serum albumin. , gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates such as glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; counterions that form salts such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™ (e.g., Tween-80), PLURONICS™, or polyethylene glycol (PEG).
[0062] In one embodiment, the present invention provides a pharmaceutical composition for use in any of the methods provided herein, comprising an antibody of the present invention and a pharma- ceutically acceptable carrier and / or excipient. In one embodiment, the formulation for the antibody of the present invention is composed of 30 mM histidine, pH 6.0, 200 mM sorbitol, and 0.02% Tween-80. In another embodiment, the formulation for the antibody of the present invention is composed of PBS, pH 6.2 (0.2 g / l KCl, 0.96 g / l KH2P04, 0.66 g / l Na2HP04×7H20, 8 g / l NaCl). EXAMPLES
[0063] Phase 1b / IIa Study Design and Concept A multicenter, randomized, double-blind, placebo-controlled study was conducted to evaluate the safety, preliminary clinical activity, and immunogenicity of multiple doses of MOR103 administered intravenously to patients with active rheumatoid arthritis.
[0064] Primary endpoints were adverse event rate and safety profile. Secondary endpoints included DAS28 score, ACR score, and EULAR28 response criteria.
[0065] The clinical trial consisted of three treatment arms. In each arm, patients received either placebo or MOR103. The MOR103 dose was 0.3 mg / kg body weight in arm 1, 1.0 mg / kg body weight in arm 2, and 1.5 mg / kg body weight in arm 3. MOR103 and placebo were administered intravenously weekly for a total of four doses.
[0066] Treatment group overview:
[0067] [Table 1]
[0068] Eligible participants in the study were patients of both sexes (male and female) aged 18 years or older. Healthy volunteers were not accepted.
[0069] The inclusion criteria for patients in the study were as follows: Rheumatoid arthritis (RA) according to the revised 1987 ACR criteria Active RA: 3 or more swollen joints and 3 tender joints in the hand with at least 1 swollen joint, excluding the PIP joints CRP>5.0 mg / L (RF and anti-CCP seronegative); CRP>2 mg / l (RF and / or anti-CCP seropositive) DAS28≦5.1 - Stable treatment plan for combined RA treatment (NSAIDs, steroids, non-biologic DMARDs) ·PPD tuberculin skin test negative The study exclusion criteria were as follows: Prior treatment with B-cell or T-cell depleting agents other than rituximab (e.g., Campath). Prior treatment with rituximab, TNF inhibitors, other biologics (e.g., anti-IL-1 therapy), and systemic immunosuppressants is permitted, provided there are drug-free periods. History of ongoing, serious, or recurrent infections Active inflammatory diseases other than RA Treatment with systemic investigational drugs within 6 months prior to screening Women of childbearing potential, except those receiving ongoing methotrexate or leflunomide Serious cardiac or pulmonary disease (including methotrexate-associated pulmonary toxicity) Liver or kidney failure EXAMPLES
[0070] Patient Recruitment and Patient Population Clinical sites for patient recruitment, screening and treatment were located in Bulgaria, Germany, the Netherlands, Poland and Ukraine.
[0071] 96 patients were enrolled in the study. 27 patients received placebo, 24 patients received MOR103 at a dose of 0.3 mg / kg, 22 patients received MOR103 at a dose of 1.0 mg / kg, and 23 patients received MOR103 at a dose of 1.5 mg / kg. Mean age and mean body mass index (BMI) were similar in all treatment groups. Key characteristics are summarized in the table below:
[0072] [Table 2]
[0073] Ninety percent of all patients in the study had been previously treated with a DMARD. The most commonly used DMARD was methotrexate (75% of all patients). The proportion of patients with a history of DMARD treatment was similar in all treatment groups.
[0074] Prior to administration of MOR103 or placebo, disease activity in all patients was measured by calculating the DAS28 score, i.e., the 28-joint disease activity score, according to accepted guidelines (see, e.g., Ann Rheum Dis (2009) 68, 954-60). The DAS28 score is a validated and commonly used method of quantifying disease status in RA patients. The mean DAS28 scores were similar in all treatment groups. EXAMPLES
[0075] Safety Profile Based on the available observed safety data, MOR103 demonstrated a favorable safety profile at all doses tested. Key findings include: No mortality was observed during the study. No infusion-related reactions were observed. Two serious adverse events (SAEs) were observed: - 1 patient in the placebo group developed paronychia.
[0076] One patient in the -0.3 mg / kg treatment group developed pleurisy. More treatment-emergent adverse events (TEAEs) were observed in the placebo group (25.9%) than in the active group (14.5%). Most TEAEs were mild. No serious TEAEs were observed in the active group.
[0077] In summary, it is concluded that treatment with MOR103 at all doses tested is safe. Two serious adverse events were observed, both in treatment arms that did not demonstrate clinical benefit (see below). Subcutaneous administration of MOR103 at doses that produce antibody drug concentrations in patients' blood equivalent to the intravenous application in this study is expected to show a similar safety profile. EXAMPLES
[0078] Efficacy – DAS28 Four and eight weeks after the first dose of MOR103 (or placebo), all patients had their DAS28 scores measured. A decrease in DAS28 score correlates with a decrease in disease severity. Results are shown in Figure 2 as the mean change compared to baseline, i.e., pre-treatment disease state.
[0079] The placebo group showed only minor changes. Patients treated with 0.3 mg / kg MOR103 showed a mild decrease in DAS28 scores, indicating slightly lower disease severity. In contrast, patients treated with 1.0 mg / kg or 1.5 mg / kg MOR103 showed a significant decrease in DAS28 scores, indicating high efficacy of MOR103 at these doses. EXAMPLES
[0080] Efficacy – ACR20 Another efficacy evaluation criterion used was the ACR20 criterion. The ACR20 criterion measures the improvement in tender or swollen joint counts and other specific parameters. The method for measuring the ACR score is highly standardized. This clinical trial used the respective appropriate guidelines. The results are shown in Figures 3 and 4. A higher score corresponds to an improvement in disease severity.
[0081] In agreement with the results of the DAS28 score (see Example 4), the ACR score also indicates a significant clinical improvement of the patient's condition upon treatment with either 1.0 mg / kg MOR103 or 1.5 mg / kg MOR103. The improvement after 4 weeks is highly significant in the 1.0 mg / kg group (p<0.0001). Taken together, the ACR20 scores support the surprising finding that the efficacy of MOR103 can already be demonstrated with a comparably small number of patients in each treatment group and a relatively short treatment period. EXAMPLES
[0082] Clinical trials with additional doses of MOR103 The clinical trial designed above is repeated with additional doses of MOR103. MOR103 is administered intravenously to patients at doses of 0.5 mg / kg (arm 1) and 0.75 mg / kg (arm 2). All other parameters are the same as in Example 1.
[0083] Both treatment arms show a favorable safety profile and demonstrate clinical efficacy as measured by DAS28 and ACR20 scores. EXAMPLES
[0084] Clinical trial of subcutaneous formulation of MOR103 The clinical trial designed above will be repeated using a subcutaneous formulation of MOR103. The subcutaneous dose of MOR103 will be increased to achieve similar MOR103 concentrations in the patient's blood as observed with intravenous treatment.
[0085] In the various treatment groups, patients receive MOR103 at 1.5 mg / kg, 2.0 mg / kg, 3.0 mg / kg and 4.0 mg / kg. The drug is administered subcutaneously either every other week, every month or every other month. All other parameters are the same as in Example 1.
[0086] All treatment arms show a favorable safety profile and demonstrate clinical efficacy as measured by DAS28 and ACR20 scores. EXAMPLES
[0087] Clinical trial of a fixed-dose subcutaneous formulation of MOR103 Example 7 is repeated with fixed doses of MOR103. In the various treatment groups, patients are administered MOR103 at fixed doses of 75 mg, 100 mg, 150 mg, 200 mg, 300 mg and 400 mg. The drug is administered subcutaneously every week, every 2 weeks, every 4 weeks or every 6 weeks. All other parameters are the same as in the above example.
[0088] All treatment arms show a favorable safety profile and demonstrate clinical efficacy as measured by DAS28 and ACR20 scores.
Claims
1. 1. A pharmaceutical composition for use in treating a patient suffering from rheumatoid arthritis comprising an anti-GM-CSF antibody together with a pharma- ceutical acceptable carrier, excipient or stabilizer, the pharma- ceutical acceptable carrier, excipient or stabilizer being a buffer that is histidine, a sugar that is sorbitol, and a non-ionic detergent that is Tween-80, the anti-GM-CSF antibody having the sequence QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGR The above composition comprises a variable heavy chain of sequence FTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS (SEQ ID NO: 8) and a variable light chain of sequence DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQ (SEQ ID NO: 9), and the treatment comprises subcutaneously administering the anti-GM-CSF antibody to the patient at a dose of 150 mg.
2. The pharmaceutical composition for use according to claim 1 , wherein the anti-GM-CSF antibody is a human monoclonal antibody.
3. The pharmaceutical composition for use according to claim 1 or 2, wherein the anti-GM-CSF antibody is administered weekly.
4. The pharmaceutical composition for use according to any one of claims 1 to 3, wherein the anti-GM-CSF antibody is administered in combination with a DMARD such as methotrexate.
Citation Information
Cited By
Curable resin materials, prepregs, resin films, metal-clad laminates, printed circuit boards, and semiconductor packages.
CN123125252A
